Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick M DillonDivision of Hematology/Oncology, Univ...
Enregistré dans:
Auteurs principaux: | Dillon PM, Brenin CM, Slingluff CL Jr |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8f13b704edc548b7967b873fe2665815 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
par: Jagosky M, et autres
Publié: (2021) -
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
par: Ayoub NM, et autres
Publié: (2019) -
Single-day HER2neu amplification assessment using chip-based digital PCR in formalin-fixed paraffin-embedded breast carcinoma tissue
par: Shah PS, et autres
Publié: (2018) -
Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
par: Xiaoshuang Lyu, et autres
Publié: (2021) -
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
par: Antolín S, et autres
Publié: (2018)